Severe Community-Acquired Bacterial Pneumonia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Severe community-acquired pneumonia (CAP) is characterized by pneumonia that necessitates supportive therapy in a critical care setting and is associated with a higher mortality rate. It is commonly observed as a multisystem disease, often leading to the failure of multiple organs. Streptococcus pneumoniae (pneumococcus), Haemophilus influenzae, and Staphylococcus aureus are frequent bacterial pathogens responsible for causing severe CAP. These bacteria can invade the lungs either through inhalation of respiratory droplets containing the bacteria or by spreading from an infection in another part of the body. Symptoms of severe community-acquired bacterial pneumonia can vary but often include the following: high fever, severe cough with greenish or bloody sputum, chest pain or discomfort, shortness of breath or difficulty breathing, rapid breathing, fatigue, and weakness, and bluish discoloration of the lips or nails due to oxygen deprivation. A significant proportion of patients with severe CAP have underlying chronic diseases, such as chronic obstructive pulmonary disease (COPD), observed in approximately one-third of the population. Most patients with severe CAP will require intubation and mechanical ventilation, particularly when they exhibit persistent hypoxemia, severe acidosis, depressed consciousness, or progressive hypercapnia. Patients with severe CAP often experience prolonged critical care admissions and face risks such as severe septic shock, renal and hepatic failure, coagulopathy, and central nervous system complications, including vascular events, encephalopathy, meningitis, and convulsions.
• The incidence of Community-acquired pneumonia ranges from 345 to 650 cases per 100,000 population in the USA.

Thelansis’s “Severe Community-Acquired Bacterial Pneumonia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Severe Community-Acquired Bacterial Pneumonia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Severe Community-Acquired Bacterial Pneumonia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Severe Community-Acquired Bacterial Pneumonia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Severe Community-Acquired Bacterial Pneumonia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033